Unicycive Therapeutics, Inc.

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

Instagram

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By selecting yes, I agree to receive marketing text messages and calls from Johnson Fistel, PLLP at the phone number provided. I understand these messages may be sent using an automatic dialing system, that consent is not a condition of purchase or receipt of services, and that message & data rates may apply. I can reply HELP for help or STOP to cancel. See our Privacy Policy and Terms.(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

For more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter regarding the resubmitted OLC NDA. The Company disclosed that the CRL was based on the same third-party manufacturing deficiencies identified in the prior June 2025 CRL. Unicycive also disclosed that the FDA had not yet conducted its inspection of the third-party manufacturing vendor as part of the review process for the resubmitted NDA.

Unicycive further stated that the FDA did not raise concerns regarding OLC’s clinical efficacy or safety data and did not request additional clinical data.

Following this news, Unicycive’s stock price declined sharply, causing significant harm to investors.

In light of these disclosures, Johnson Fistel is investigating whether Unicycive made false or misleading statements or failed to disclose material information. If you suffered losses, or are a long-term holder of Unicycive stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.

Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations
(619) 814-4471
jimb@johnsonfistel.com